Uncovering the anti-cancer mechanisms of Immuno-Oncology

Screening Platform of Novel Drug Combination for the Regulation of Tumor Microenvironment

The tumor microenvironment is an important field of research for it contains key components to control immune response. GNTbm has built a reliable screening platform, through which has been successfully developed three potent and novel drug combinations including GNTbm-CC-01, GNTbm-CC-02 and GNTbm-EC-02.

These potent and novel drug combinations mainly reduced the number and function of immunosuppressive cells such as MDSCs (myeloid-derived suppressor cells), Treg (regulatory T cells), and TAM (tumor-associated macrophages), and therefore significantly activate CTL (cytotoxic T lymphocytes) and NK (natural killer) cells to kill cancer cells. These drug combinations possessed immunomodulatory activity and can induce the generation of memory T cells to surveil and kill cancer cells carrying the same specific antigen for recognition. These memory T cells possess the capability to activate host immune system to quickly recognize and attack the cancer cells. Therefore, after the discontinuation of treatment with these drug combinations, the benefits of inhibition of tumor growth still sustain, which makes these novel drug combinations highly potential new therapy in the area of cancer immunotherapy.


Screening Platform of New Generation of Tumor Microenvironment-Regulating NCE

GNTbm has independently developed and designed new tumor microenvironment-regulating small molecules, class I HDAC inhibitors. Through lead optimization, it will enhance the inhibitory activity against specific HDAC enzymes to achieve higher survival rate during treatment. With well established animal models evaluation processes and experiences, new generation of small molecule tumor microenvironment-regulating drugs are screened and under investigation.